The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for ...

This study is committed to searching for inhibitors of deacetylase SIRT2 within the natural product database via computer-aided drug design techniques. A comprehensive computer-aided drug design ...

The first patient has been enrolled in a Phase 1 trial by the NHLBI that's evaluating fostamatinib as a treatment for sickle cell disease.

1. Chemotherapy agents: Medications like anthracyclines and trastuzumab are known to cause cardiotoxicity, leading to reduced heart function and even heart failure. 2. Non-Steroidal Anti-Inflammatory ...

Naproxcinod [(S)-2-(6-Methoxy-2-naphthyl)propanoic acid 4-nitrooxybutyl ester], that is, NO-naproxen, is the first of the class of cyclooxygenase-inhibiting NO donators, and is currently in Phase ...

Background Cangrelor, an intravenous P2Y12-receptor inhibitor, is a reversible and short-acting antithrombotic medication non-inferior to irreversible glycoprotein IIb/IIIa inhibitors (GPIs) like ...

Human platelet lysates (HPL) are abundant in bioactive factors, and numerous studies have demonstrated their beneficial effects on neurological diseases, including their anti-neuroinflammatory ability ...

IPA: Inhibition of platelet aggregation ... The combined use of antiplatelet drugs acting through different mechanisms is important in antithrombotic treatment of patients with cardiovascular ...

This review will provide some recent progress of the use of platelet concentrates to treat lesions on ... The most important factor in its pathogenesis is the inhibition of osteoclast activity and ...

All COX2 inhibitors undergo oxidative drug metabolism by cytochrome P450 ... 50 is not only a potent inhibitor of platelet aggregation, but also interferes with processes leading to hypertension ...